ViroSpot microneutralization assay for antigenic characterization of human influenza viruses (Q40430942)

20 September 2017

ViroSpot microneutralization assay for antigenic characterization of human influenza viruses (English)

1 reference

20 September 2017

6

Marion P G Koopmans

1 reference

20 September 2017

7

Guus F Rimmelzwaan

1 reference

20 September 2017

Carel A van Baalen

1

1 reference

20 September 2017

Rienk E Jeeninga

2

1 reference

20 September 2017

Germaine H W M Penders

3

1 reference

20 September 2017

Brenda van Gent

4

1 reference

20 September 2017

Ruud van Beek

5

1 reference

20 September 2017

language of work or name

English

0 references

publication date

26 November 2016

1 reference

20 September 2017

7

1 reference

based on heuristic

inferred from page(s)

published in

Vaccine

1 reference

20 September 2017

35

1 reference

20 September 2017

1

1 reference

20 September 2017

46-52

1 reference

Mapping the antigenic and genetic evolution of influenza virus

20 September 2017

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.11.060

Influenza B viruses: not to be discounted

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.11.060

Effectiveness of seasonal influenza vaccine in preventing laboratory-confirmed influenza in primary care in the United Kingdom: 2014/15 end of season results

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.11.060

Interim estimates of 2014/15 vaccine effectiveness against influenza A(H3N2) from Canada's Sentinel Physician Surveillance Network, January 2015.

7 January 2021

2 references

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.11.060

7 January 2021

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.11.060

inferred from DOI database lookup

7 January 2021

based on heuristic

Substitutions near the receptor binding site determine major antigenic change during influenza virus evolution

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.11.060

Neuraminidase receptor binding variants of human influenza A(H3N2) viruses resulting from substitution of aspartic acid 151 in the catalytic site: a role in virus attachment?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.11.060

Optimization of a micro-neutralisation assay and its application in antigenic characterisation of influenza viruses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.11.060

Detection of nonhemagglutinating influenza a(h3) viruses by enzyme-linked immunosorbent assay in quantitative influenza virus culture

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.11.060

Optimization of an enzyme-linked lectin assay suitable for rapid antigenic characterization of the neuraminidase of human influenza A(H3N2) viruses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.11.060

New low-viscosity overlay medium for viral plaque assays

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.11.060

Identification of Hemagglutinin Residues Responsible for H3N2 Antigenic Drift during the 2014-2015 Influenza Season

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.11.060

Strengthening the influenza vaccine virus selection and development process. Report of the 3rd WHO Informal Consultation for Improving Influenza Vaccine Virus Selection held at WHO headquarters, Geneva, Switzerland, 1-3 April 2014

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.11.060

Detection of antibody to avian influenza A (H5N1) virus in human serum by using a combination of serologic assays.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.11.060

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/J.VACCINE.2016.11.060

1 reference

20 September 2017

1 reference